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Abstract— Circulating cell-free DNA (cfDNA) is a powerful 
cancer biomarker for establishing targeted therapies or 
monitoring patients’ treatment. However, current cfDNA 
characterization is severely limited by its low concentration, 
requiring the extensive use of amplification techniques. Here 
we report that the µLAS technology allows us to quantitatively 
characterize the size distribution of purified cfDNA in a few 
minutes, even when its concentration is as low as 1 pg/µL. 
Moreover, we show that DNA profiles can be directly 
measured in blood plasma with a minimal conditioning process 
to speed up considerably speed up the cfDNA analytical chain. 
I. INTRODUCTION 
The analysis of cfDNA in body fluids gains in popularity 
for the management and follow-up of solid tumors. The 
detection of alterations in cfDNA is likely to guide the 
administration of cancer drugs as first-line treatments  or to 
fight emerging resistance or relapse (1). Various types of DNA 
alterations have been reported in cfDNA, including point 
mutations or copies number variation (2). In many instances, 
these alterations were identical to those found in the primary 
tumor, confirming the relevance of clinical strategies based on 
monitoring genetic alterations in cfDNA. Additionally, the 
analysis of cfDNA concentration has often shown an increase 
in patients’ samples correlated with the disease stage (3), 
although the association of cfDNA concentration with an 
integrity index increases the predictive value of total cfDNA 
profile (4). Here we report the µLAS (µLaboratory for Analysis 
& Separation) microfluidic technology (5) is relevant for 
cfDNA analysis. We start with a demonstration of the 
performance of µLAS in the 100-1500 bp size range, which 
reaches a limit of detection (LOD) of 10 pg/mL and a sizing 
precision of 3%, We then perform molecular analyses on a 
small cohort of patients with different types of cancers, and 
report that the integrity index indeed represents a biomarker for 
cancer relapse. Finally, we demonstrate that the technology can 
be operated directly on blood plasma with minimal 
conditioning protocols.  
II. µLAS TECHNOLOGY 
A.  µLAS operating principle 
We have recently reported the principle of the µLAS 
microfluidic technology to perform the operations of DNA 
concentration and separation simultaneously (5). It relies on the 
manipulation of DNA molecules in a pressure-driven 
viscoelastic flow in combination with a counter-electrophoretic 
force. DNA undergoes a viscoelastic force oriented towards the 
channel walls, the amplitude of which is dependent on its 
molecular weight (MW). The viscoelastic buffer is composed 
of 1X Tris-Borate-EDTA (TBE, Sigma) supplemented with 1.3 
MDa Polyvinylpyrrolidone (PVP, Sigma) dissolved at 5% in 
weight, and YOYO-1 (Molecular Probes) at a 1:10 DNA:dye 
ratio for fluorescence labelling. This technology can also be 
operated in a linear channel for size separation operations. 
Concentration is achieved by flowing the DNA solution 
through a constriction. The funnel shape allows us to modulate 
the amplitude of the electric and hydrodynamic fields, and 
hence to generate viscoelastic forces of different amplitudes 
ahead and past the constriction (Fig. 1A). By setting the 
pressure drop and voltage appropriately, it is possible to switch 
from a mode of migration with low forces and molecules 
predominantly at the centerline of the channel, thus 
preferentially conveyed by hydrodynamics, to a mode of high 
forces with molecules stacked to the wall with a dominant 
contribution of electrophoresis. Overall, DNA velocity is null 
at the constriction, and DNA molecules accumulate over time 
because they are transported by hydrodynamics or 
electrophoresis forward or backward to the funnel, respectively.  
This technology relies on conventional pressure and voltage 
actuation systems. So, it can be operated in microfluidic format 
using conventional photolithography and plasma etching of 
silicon (Fig. 1B), as well as on capillary electrophoresis 
instruments (CE, Fig. 1C). The latter option allows us to 
compare the performance of µLAS to commercial standards. 
B. Determination of the sizing accuracy & limit of detection 
We first calibrated the µLAS technology with a dual chip 
design with a reference channel (upper half of Fig. 2) and a 
calibrated sample with three DNA fragments of 466, 798 and 
1512 bp. We fixed the DNA concentration within each band to 
80 pg μL−1, which is about three orders of magnitude lower than 
the typical DNA concentration used for slab gel 
electrophoresis. We empirically defined the pressure and 
voltage to be able to visualize all 9 bands of the ladder 
simultaneously (Fig. 2). This yielded parameters of 6 bar and 
82 V, corresponding to a maximum flow velocity and an 
electric field of ~7 cm s−1 and 690 kV m−1, respectively. We set 
the time of enrichment to 30 s for these experiments. From the 
resulting fluorescence micrographs, we extracted the intensity 
profile along the symmetry axis of the two funnels (blue and 
  
red arrows in Fig. 2) and used linear extrapolation between the 
ladder bands to determine the size of the three target bands. We 
estimated the size of these three bands to be 456, 788 and 1550 
bp, showing that the difference in DNA length between the 
readout and the nominal size was less than 3%, i.e., an accuracy 
of ~10 bp for a fragment of 350 bp. 
We then evaluated the lower limit of detectable DNA 
concentration after 5 minutes of concentrating and separating 
fragments with a reference 100 bp ladder at a total 
concentration of 1 pg µL−1, or ~100 fg µL−1 per band. As 
expected, we observed a build-up in intensity for all bands of 
the ladder within 5 minutes (Fig. 1B). Given that current high-
sensitivity equipment like the Bioanalyzer or the Fragment 
Analyzer have a lower limit of detection of about ~5 pg µL−1, 
according to the manufacturers, the sensitivity of µLAS was 50-
fold greater. The LOD can be further improved by increasing 
the time of concentration to 25 minutes, as carried out with CE. 
Using serial dilutions of the 100 bp ladder, we focused on the 3 
bands of 200, 300, and 1000 bp and deduced respective LODs 
of 0.07, 0.04, and 0.01 pg µL−1 (data not shown). These 
performances are thus relevant to perform size analysis of 
highly diluted samples, in particular purified cfDNA samples, 
as shown in the following paragraph.  
III. CFDNA PROFILING 
A. cfDNA profiles 
µLAS technology was then applied to the analysis of 
cfDNA extracted from blood plasma. cfDNA extraction was 
carried out starting from 2 mL of fresh plasma using the 
recommended protocol of Qiagen. We assayed clinical samples 
from two research teams, each cohort including healthy 
individuals and patients with Colorectal Cancer (CRC), lung 
cancer (NLCSC), or melanoma. The cfDNA profiles typically 
contained a predominant thin peak around 150 bp, a second 
peak around 300 bp, which is usually smaller and wider, 
followed or not by a third even smaller and larger peak around 
450-500 bp, as well as by various amounts of high MW DNA 
(greater than 1 kb, upper panel in Fig. 3A). This high MW 
fraction may come from genomic DNA of leucocytes during 
pre-analytical stages, or may reflect a physiological 
phenomenon. This profile was detected for cfDNA samples 
over a wide range of total DNA concentration spanning 1-500 
pg/µL. This typical profile is consistent with previous reports 
obtained with highly concentrated cfDNA samples analyzed 
with the bioAnalyzer™ (Agilent) (6). Notably however, in our 
hands (data not shown), when using such state-of-the-art 
electrophoresis systems, cfDNA profiles could only be assayed 
for highly concentrated samples with a total DNA concentration 
larger than ~250 pg/µL. 
B. Validation of the results 
In order to consolidate the quantification of cfDNA 
performed with µLAS, we compared the total cfDNA 
concentration to the results of fluorimetry (Qubit™) and digital 
droplet PCR (dPCR). We first analyzed a set of samples 
composed of 8 healthy individuals and 14 metastatic colorectal 
cancers (sample set 1). The correlation between the Qubit™ 
and µLAS total cfDNA was associated to a Spearman 
correlation coefficients of 0.8 (left panel in Fig. 3B). The linear 
regression yielded a proportionality factor between µLAS and 
Qubit data of 0.82. This value is close to 1, yet a slightly smaller 
likely because we only quantify DNA molecules in the range 
0.1 to 1.6 kb with µLAS in the chosen experimental conditions, 
whereas the Qubit™ concentration is insensitive to DNA MW. 
The same sample set was characterized by dPCR with a 60 bp 
amplicon in the KRAS gene (central panel of Fig. 3B). The 
Spearman correlation coefficient was 0.8 with a linear 
regression associated to proportionality factor for µLAS over 
dPCR concentrations of 1.2, supporting the relevance of our 
technology to measure total cfDNA concentration. We finally 
focused on 32 melanoma patients (sample set 2). The 
correlation plot was quite clear again with a Spearman 
correlation coefficient 0.89 (right panel of Fig. 4B). Therefore, 
cfDNA titration by µLAS is consistent with state-of-the-art 
sensing technologies. 
IV. DIRECT CFDNA SENSING IN BLOOD PLASMA 
Because the purification of cfDNA is a time-consuming and 
labor-intensive operation, we set out to establish that profiling 
could be performed directly in plasma. We therefore optimized 
a step of protein digestion with proteinase K during 2 hours then 
centrifuged the sample at 10000 g during 10 minutes and added 
the visco-elastic solution. Using this approach, we could detect 
the three main low MW bands characteristic of cfDNA profiles 
(Fig. 4). Notably, this process is operated in solution containing 
high amounts of salt, which are typically not adequate to any 
commercial technology for diluted DNA samples analysis. 
V. CONCLUSION 
We prove that µLAS is a high sensitivity DNA detection 
technology that allows cfDNA processing without any steps of 
molecular amplification. 
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Figure 1: BIABooster system for DNA concentration, separation, and detection. (A) DNA concentration can be performed using a 
constriction and electro-hydrodynamic actuation. DNA transport is dominated by hydrodynamics (blue arrows) ahead of the constriction and 
by electrophoresis (green arrows) downstream, so DNA molecules accumulate at the position where their velocity is null. (B) Detection of 
DNA ladder fragments at 100 fg µL−1. The time series in the upper panel shows fluorescence intensity at the constriction using a 100 bp DNA 
ladder diluted at 1 pg µL−1. Taking the fluorescence micrograph at t=0 s as a reference, the lower panel represents background subtracted 
intensity profiles, in which the presence of the 9 bands of the ladder appear after 5 minutes. Scale bar = 300 µm. (C) Experimental 
demonstration of the concentration with two hafted capillaries of different inner diameters 100 and 20 µm, as shown in the upper panel. The 
fluorescence micrograph in the lower panel shows the concentration of 5 kb DNA molecules at the junction. The final device is loaded in an 
Agilent capillary electrophoresis instrument. Concentration and detection areas are marked with blue and red arrowheads, respectively. 
 
 
Figure 2: Microfluidic chip for DNA separation and size identification. (A) µLAS chip with two independent channels actuated with the 
same pressure and voltage. Each channel contains one funnel, in which we operate DNA separation and concentration estimation in line. We 
used a reference signal with a DNA ladder in the upper channel, and conveyed the analyte in the bottom channel. The 1% TAE agarose gel 
shown was loaded with 500 ng of DNA/well. (B) A fluorescence micrograph shows the two channels after concentration during 30 s using a 
target sample with three fragments of 466, 798 and 1512 bp at 80 pg µL−1. Scale bar = 300 µm. (C) The two plots represent the intensity profile 
along the two arrows represented in panel (B). The raw data is represented in black and the fits with Gaussian functions by blue and red colors. 




Figure 3: Profiling cfDNA with BIABooster system. (A) typical cfDNA profiles for concentration from 1 to 500 pg/µL (75-1650 bp range). 
cfDNA samples represented here are from melanoma patients. (B) The left plot shows the correlation between cfDNA concentrations of sample 

























Figure 4: Profiling cfDNA directly from plasma. The 
fluorescence micrograph shows the cfDNA profile after the 
processing of plasma with proteinase-K and mixing it with the 
viscoelastic solution containing 5% PVP. 
